Cholangiocarcinoma News

Cost-Effectiveness of GemCis with or without Durvalumab in Patients with Advanced CCA

March 2023, Vol 4, No 1

First-line standard of care for patients with advanced cholangiocarcinoma (CCA) has evolved from a chemotherapy-only regimen with gemcitabine/cisplatin (GemCis) to include the immune checkpoint inhibitor durvalumab based on results from TOPAZ-1 showing that the addition of durvalumab improved progression-free survival (PFS) and overall survival (OS) compared with GemCis alone. Although clinical benefit with the addition of durvalumab to GemCis has been proved, affordability of the regimen is still a concern. Dr J. Alberto Maldonado presented results from a cost analysis of this treatment regimen.

Unit prices of durvalumab and GemCis were calculated using the LexiComp, and the drug cost per cycle was calculated for each drug assuming an average patient surface area of 1.9 m2 for men and 1.6 m2 for women. Excluded costs included cost of administration, adverse events, and follow-up. Similar to the TOPAZ-1 study design, the first 8 cycles included either durvalumab (day 1) plus GemCis (days 1 and 8) or placebo (day 1) plus GemCis (days 1 and 8) every 3 weeks, followed by durvalumab or placebo alone every 4 weeks until disease progression. The sum of all treatment cycles was included as the total treatment cost, and cost per life-year gained was calculated using a combination of total cost per year and treatment duration.

The drug cost per cycle was $13,797 for durvalumab, $282 for gemcitabine, and $87 for cisplatin. The total monthly cost for GemCis alone was $246 compared with $17,492 with the addition of durvalumab, a difference of $17,246. The median PFS in TOPAZ-1 was 7.2 months in the durvalumab group versus 5.7 months in the placebo group, a difference of 1.5 months. The difference in cost between GemCis alone and GemCis plus durvalumab, $17,246, multiplied by PFS months gained, 1.5 months, with the addition of durvalumab resulted in an estimated cost of $25,869 to gain 1.5 months of PFS. Total yearly cost by treatment arm was also higher for the durvalumab plus GemCis group ($209,899 vs $2949).

Although the results from TOPAZ-1 sparked excitement with promising PFS and OS benefit, cost-effectiveness evaluation is important to address financial toxicity for patients with CCA and suggests a need for additional research to explore cost-effective solutions.

Source: Maldonado JA, Greten TF, Monge C. Cost-effectiveness of gemcitabine plus cisplatin with and without durvalumab in patients with advanced cholangiocarcinoma. Poster presented at: ASCO Gastrointestinal Cancers Symposium, January 19-21, 2023; San Francisco, CA. Abstract 498.

Related Items

Characterization of Long-Term Survivors in TOPAZ-1
March 2023, Vol 4, No 1
Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.
MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC
March 2023, Vol 4, No 1
The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.
Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study
March 2023, Vol 4, No 1
Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.
Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC
March 2023, Vol 4, No 1
CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.
Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements
March 2023, Vol 4, No 1
Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.
Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC
March 2023, Vol 4, No 1
The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.
JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection
March 2023, Vol 4, No 1
A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.
Impact of Gene Expression in 5-FU Metabolic Pathways on Outcomes in Patients Enrolled in JCOG1202
March 2023, Vol 4, No 1
Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.
Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151
March 2023, Vol 4, No 1
Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.
Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC
March 2023, Vol 4, No 1
The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: